`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
` EXHIBIT B
`
`EXHIBIT B
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_____________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_____________________
`
`
`PHIGENIX, INC.
`Petitioner
`
`v.
`
`IMMUNOGEN, INC.
`Patent Owner
`
`_____________________
`
`CASE: IPR2014-00676
`Patent 8,337,856
`_____________________
`
`
`IMMUNOGEN, INC.’S SUPPLEMENTAL
`EVIDENCE UNDER 37 C.F.R. § 42.64(b)(2)
`
`
`
`
`
`ImmunoGen, Inc.’s Supplemental Evidence Under 37 C.F.R. § 42.64(b)(2)
`IPR2014-00676
`In response to Phigenix, Inc.’s Objections to Exhibits 2041, 2062, 2072,
`
`2073, 2083, 2103, 2105, 2116, 2123, 2127, 2131, 2134, 2147, 2204, 2216, 2218,
`
`2220, 2226-2238, 2240-2244, 2247, 2252-2261, 2266-2271, 2275, 2303, 2318-
`
`2320, 2325, 2334, 2335, 2340-2342, and 2344-2346, served on January 29, 2015,
`
`Patent Owner ImmunoGen, Inc. hereby serves supplemental evidence. Service of
`
`confidential supplemental evidence related to Exhibits 2240-2244, 2256, 2319, and
`
`2320 is made subject to the Patent Trial and Appeal Board’s Default Protective
`
`Order provided in Appendix B of the Office Patent Trial Practice Guide, 77 Fed.
`
`Reg. 48,756, 48,771 (Aug. 14, 2012).
`
`Phigenix’s Objections were served on January 29, 2015; therefore,
`
`ImmunoGen’s service of supplemental evidence is timely under 37 C.F.R. §
`
`42.64(b)(2).
`
`
`
`
`
`
`
`
`Date: February 12, 2015
`1100 New York Avenue, N.W.
`Washington, D.C. 20005-3934
`(202) 371-2600
`
`STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
`
`
`/Eldora L. Ellison/
`Eldora L. Ellison
`Lead Counsel for Patent Owner
`ImmunoGen, Inc.
`Registration No. 39,967
`
`
`
`2
`
`
`
`CERTIFICATE OF SERVICE (37 C.F.R. § 42.6(e))
`
`In response to Phigenix, Inc.’s Objections to Exhibits 2041, 2062, 2072,
`
`2073, 2083, 2103, 2105, 2116, 2123, 2127, 2131, 2134, 2147, 2204, 2216, 2218,
`
`2220, 2226-2238, 2240-2244, 2247, 2252-2261, 2266-2271, 2275, 2303, 2318-
`
`2320, 2325, 2334, 2335, 2340-2342, and 2344-2346, served on January 29, 2015,
`
`the undersigned hereby certifies that supplemental evidence was served in its
`
`entirety on February 12, 2015, upon the following parties via email:
`
`
`
`
`Ping Wang
`
`ANDREWS KURTH, LLP
`1350 I Street NW, Suite 1100
`Washington, DC 20005
`
`Tel: (202) 662-3042
`
`
`Fax: (202) 662-3729
`
`
`PingWang@andrewskurth.com
`
`
`
`
`
`
`
`Gregory Porter
`ANDREWS KURTH, LLP
`600 Travis, Suite 4200
`Houston, TX 77002
`Tel: (713) 220-4621
`Fax: (713) 220-4257
`GregPorter@andrewskurth.com
`
`STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
`
`
`/ Eldora L. Ellison /
`Eldora L. Ellison
`Lead Counsel for Patent Owner
`ImmunoGen, Inc.
`Registration No. 39,967
`
`
`Date: February 12, 2015
`1100 New York Avenue, N.W.
`Washington, D.C. 20005-3934
`(202) 371-2600
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`